Skip to main content
18 February 2019
Last updated:
Monday 18 February 2019

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Moderna exercises option for rights to Avacta technology

Sunday 10 February 2019
Country

United Kingdom

Avacta Group Plc, which is developing a new type of protein therapeutic, is to license certain assets to Moderna Therapeutics Inc against a potential therapeutic target which has been part of an ongoing research collaboration between the two companies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Company News
Finance, Grants, Deals

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Donato Spota to become CFO at Hansa Biopharma
Thursday February 7 2019
Georgia Gavriilidou joins Sidley Austin
Thursday February 7 2019
Alan Knox becomes CEO at Primex
Thursday February 7 2019
Kiadis appoints Robert Friesen as CSO
Thursday February 7 2019
Samantha Paston to head research at Scancell
Thursday February 7 2019

© 2018 Evernow Publishing Ltd. Powered by Drupal.